King Pharmaceuticals KG Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

LazardLAZ

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's accrued expenses and other liabilities?: King Pharmaceuticals (KG) reported accrued expenses and other liabilities of $5.56M in Q1 2026.
How has King Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?: King Pharmaceuticals's accrued expenses and other liabilities increased by 2369.0% year-over-year, from -$245K to $5.56M.